The National Institutes of Health (NIH) is offering this crucial grant to support pioneering research into advanced strategies for the in vivo delivery of gene therapeutics aimed at achieving an HIV cure. This grant is specifically for developing and validating innovative methods to efficiently and precisely target and deliver anti-HIV gene therapies to designated cells within the living body. The core purpose of this funding opportunity is to overcome current limitations in gene therapy delivery, thereby enhancing therapeutic efficacy and accelerating progress towards a functional cure for HIV/AIDS. Researchers are encouraged to submit proposals that promise significant advancements in delivery technology, contributing fundamentally to global HIV eradication efforts.
Opportunity ID: 329516
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-AI-20-076 |
Funding Opportunity Title: | New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.242 — Mental Health Research Grants |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Oct 20, 2020 |
Last Updated Date: | Oct 20, 2020 |
Original Closing Date for Applications: | Mar 17, 2023 |
Current Closing Date for Applications: | Mar 17, 2023 |
Archive Date: | Apr 22, 2023 |
Estimated Total Program Funding: | – |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | City or township governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts Public and State controlled institutions of higher education For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | The purpose of this Funding Opportunity Announcement (FOA) is to support research on the development and validation of innovative strategies to deliver anti-HIV gene therapies efficiently to specific target cells in vivo. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-076.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Folder 329516 Full Announcement-RFA-AI-20-076 -> RFA-AI-20-076-Full-Announcement.pdf
Packages
Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-F | Use for due dates on or before January 24, 2022 | PKG00263843 | Feb 17, 2021 | Jan 24, 2022 | View | |
FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269853 | Oct 28, 2021 | Jan 24, 2023 | View | |
FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277839 | Nov 01, 2022 | Mar 17, 2023 | View |
Package 1
Mandatory forms
329516 RR_SF424_2_0-2.0.pdf
329516 PHS398_CoverPageSupplement_5_0-5.0.pdf
329516 RR_OtherProjectInfo_1_4-1.4.pdf
329516 PerformanceSite_2_0-2.0.pdf
329516 RR_KeyPersonExpanded_2_0-2.0.pdf
329516 PHS398_ResearchPlan_4_0-4.0.pdf
329516 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
329516 RR_Budget_1_4-1.4.pdf
329516 RR_SubawardBudget30_1_4-1.4.pdf
329516 PHS398_ModularBudget_1_2-1.2.pdf
329516 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
329516 RR_SF424_5_0-5.0.pdf
329516 PHS398_CoverPageSupplement_5_0-5.0.pdf
329516 RR_OtherProjectInfo_1_4-1.4.pdf
329516 PerformanceSite_4_0-4.0.pdf
329516 RR_KeyPersonExpanded_4_0-4.0.pdf
329516 PHS398_ResearchPlan_4_0-4.0.pdf
329516 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
329516 RR_Budget_3_0-3.0.pdf
329516 RR_SubawardBudget30_3_0-3.0.pdf
329516 PHS398_ModularBudget_1_2-1.2.pdf
329516 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
329516 RR_SF424_5_0-5.0.pdf
329516 PHS398_CoverPageSupplement_5_0-5.0.pdf
329516 RR_OtherProjectInfo_1_4-1.4.pdf
329516 PerformanceSite_4_0-4.0.pdf
329516 RR_KeyPersonExpanded_4_0-4.0.pdf
329516 PHS398_ResearchPlan_5_0-5.0.pdf
329516 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
329516 RR_Budget_3_0-3.0.pdf
329516 RR_SubawardBudget30_3_0-3.0.pdf
329516 PHS398_ModularBudget_1_2-1.2.pdf
329516 PHS_AssignmentRequestForm_3_0-3.0.pdf